FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Lichtenstein

Research Profile

Disorders

Multiple Myeloma

Anatomy

Physiology

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Patrick Frost; Joseph Gera; Bao Hoang; Veena Mysore; Yijiang Shi; Eileen Berlanger; Alan Lichtenstein
Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.
Bao Hoang; Angelica Benavides; Patrick Frost; Joseph Gera; Yijiang Shi; Yonghui Yang; Alan Lichtenstein
The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
Joseph Gera; Alan Lichtenstein
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Lichtenstein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Patrick Frost; Joseph Gera; Bao Hoang; Veena Mysore; Yijiang Shi; Eileen Berlanger; Alan Lichtenstein
Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.
Journal of oncology 2013;2013():897025.
2012: Bao Hoang; Angelica Benavides; Patrick Frost; Joseph Gera; Yijiang Shi; Yonghui Yang; Alan Lichtenstein
The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
The Journal of biological chemistry 2012;287(26):21796-805.
2011: Joseph Gera; Alan Lichtenstein
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
Leukemia & lymphoma 2011;52(10):1857-66.
2011: Jheralyn Martin; Janine Masri; Cheri Cloninger; Brent Holmes; Nicholas Artinian; Alexander Funk; Teresa Ruegg; Lauren Anderson; Tariq Bashir; Andrew Bernath; Alan Lichtenstein; Joseph Gera
Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.
The Journal of biological chemistry 2011;286(18):16402-13.
2011: Yijiang Shi; Patrick Frost; Bao Hoang; Angelica Benavides; Joseph Gera; Alan Lichtenstein
IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.
The Journal of biological chemistry 2011;286(1):67-78.
2010: Bao Hoang; Patrick Frost; Yijiang Shi; Eileen Belanger; Angelica Benavides; Gholam Pezeshkpour; Susanna Cappia; Tommasina Guglielmelli; Joseph Gera; Alan Lichtenstein
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Blood 2010;116(22):4560-8.
2009: Bao Hoang; Angelica Benavides; Yijiang Shi; Patrick Frost; Alan Lichtenstein
Effect of autophagy on multiple myeloma cell viability.
Molecular cancer therapeutics 2009;8(7):1974-84.
2008: Sanjai Sharma; Alan Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.
Blood 2008;112(4):1338-45.
2007: Yijiang Shi; Tony Reiman; Weiqun Li; Christopher A Maxwell; Subrata Sen; Linda M Pilarski; Tracy R Daniels; Manuel L Penichet; Rick Feldman; Alan Lichtenstein
Targeting aurora kinases as therapy in multiple myeloma.
Blood 2007;109(9):3915-21.
2007: Patrick Frost; Yijiang Shi; Bao Hoang; Alan Lichtenstein
AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Oncogene 2007;26(16):2255-62.
2006: Bao Hoang; Li Zhu; Yijiang Shi; Patrick Frost; Huajun Yan; Sanjai Sharma; Sherven Sharma; Lee Goodglick; Steven M Dubinett; Alan Lichtenstein
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.
Blood 2006;107(11):4484-90.
2006: Huajun Yan; Patrick Frost; Yijiang Shi; Bao Hoang; Sanjai Sharma; Myrna Fisher; Joseph Gera; Alan Lichtenstein
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Cancer research 2006;66(4):2305-13.
2005: Harnisha Dalwadi; Kostyantyn Krysan; Nathalie Heuze-Vourc'h; Mariam Dohadwala; David Elashoff; Sherven Sharma; Nicholas Cacalano; Alan Lichtenstein; Steven M Dubinett
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7674-82.
2005: Yijiang Shi; Huajun Yan; Patrick Frost; Joseph Gera; Alan Lichtenstein
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Molecular cancer therapeutics 2005;4(10):1533-40.
2005: Yijiang Shi; Anushree Sharma; Hong Wu; Alan Lichtenstein; Joseph Gera
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.
The Journal of biological chemistry 2005;280(12):10964-73.
2004: Patrick Frost; Farhad Moatamed; Bao Hoang; Yijiang Shi; Joseph Gera; Huajun Yan; Philip Frost; Jay Gibbons; Alan Lichtenstein
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
Blood 2004;104(13):4181-7.
2004: Jung-hsin Hsu; Yijiang Shi; Patrick Frost; Huajun Yan; Bao Hoang; Sanjai Sharma; Joseph Gera; Alan Lichtenstein
Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways.
Oncogene 2004;23(19):3368-75.
2003: Yijiang Shi; Joseph Gera; Jung-hsin Hsu; Brian Van Ness; Alan Lichtenstein
Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
Molecular cancer therapeutics 2003;2(6):563-72.
2003: Liping Hu; Yijiang Shi; Jung-hsin Hsu; Joseph Gera; Brian Van Ness; Alan Lichtenstein
Downstream effectors of oncogenic ras in multiple myeloma cells.
Blood 2003;101(8):3126-35.
2003: Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary J Schiller; Alan Lichtenstein; Tomas Ganz
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.
Blood 2003;101(7):2461-3.
2002: Yijiang Shi; Joseph Gera; Liping Hu; Jung-hsin Hsu; Robert Bookstein; Weiqun Li; Alan Lichtenstein
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Cancer research 2002;62(17):5027-34.
2002: Yijiang Shi; Jung-hsin Hsu; Liping Hu; Joseph Gera; Alan Lichtenstein
Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.
The Journal of biological chemistry 2002;277(18):15712-20.
2002: Jung-hsin Hsu; Yijiang Shi; Liping Hu; Myrna Fisher; Thomas F Franke; Alan Lichtenstein
Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.
Oncogene 2002;21(9):1391-400.
2001: J Hsu; Y Shi; S Krajewski; S Renner; M Fisher; J C Reed; T F Franke; Alan Lichtenstein
The AKT kinase is activated in multiple myeloma tumor cells.
Blood 2001;98(9):2853-5.
2000: Y Tu; A Gardner; Alan Lichtenstein
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Cancer research 2000;60(23):6763-70.
2000: S Renner; J Weisz; S Krajewski; M Krajewska; J C Reed; Alan Lichtenstein
Expression of BAX in plasma cell dyscrasias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2371-80.
1998: FH Xu; S Sharma; A Gardner; Y Tu; A Raitano; C Sawyers; Alan Lichtenstein
Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway.
Blood 1998;92(1):241-51.
1998: A Aparicio; A Gardner; Y Tu; A Savage; James Berenson; Alan Lichtenstein
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Leukemia 1998;12(2):220-9.
1998: Y Tu; S Renner; F Xu; A Fleishman; J Taylor; J Weisz; Robert A Vescio; Matthew B Rettig; James Berenson; S Krajewski; J C Reed; Alan Lichtenstein
BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Cancer research 1998;58(2):256-62.
1998: Gary J Schiller; Robert A Vescio; Cesar O Freytes; G Spitzer; M Lee; C H Wu; J Cao; J C Lee; Alan Lichtenstein; Michael Lill; R Berenson; James Berenson
Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
Bone marrow transplantation 1998;21(2):141-5.
1997: A Gardner; FH Xu; C Fady; Theodore A Sarafian; Y Tu; Alan Lichtenstein
Evidence against the hypothesis that BCL-2 inhibits apoptosis through an anti-oxidant effect.
Cell death and differentiation 1997;4(6):487-96.
1997: J W Bailet; Alan Lichtenstein; G Chen; R A Mickel
Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.
Archives of otolaryngology--head & neck surgery 1997;123(8):855-62.
1996: Y Tu; F H Xu; J Liu; Robert A Vescio; J Berenson; C Fady; Alan Lichtenstein
Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.
Blood 1996;88(5):1805-12.
1996: K B Briskin; C Fady; M Wang; Alan Lichtenstein
Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha.
Archives of otolaryngology--head & neck surgery 1996;122(5):559-63.
1995: K B Briskin; C Fady; R A Mickel; M Wang; Alan Lichtenstein
Inhibition of head and neck squamous cell carcinoma cell lines by transforming growth factor-beta.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1995;112(6):728-34.
1995: Alan Lichtenstein; Y Tu; C Fady; Robert A Vescio; J Berenson
Interleukin-6 inhibits apoptosis of malignant plasma cells.
Cellular immunology 1995;162(2):248-55.
1995: C Fady; A Gardner; F Jacoby; K Briskin; Y Tu; Ingrid Schmid; Alan Lichtenstein
Atypical apoptotic cell death induced in L929 targets by exposure to tumor necrosis factor.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(1):71-80.
1994: Steven M Dubinett; Min Huang; Alan Lichtenstein; william mcbride; J Wang; G Markovitz; D Kelley; W W Grody; L E Mintz; S Dhanani
Tumor necrosis factor-alpha plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation.
Cellular immunology 1994;157(1):170-80.
1994: D M Kelley; Alan Lichtenstein; J Wang; A N Taylor; Steven M Dubinett
Corticotropin-releasing factor reduces lipopolysaccharide-induced pulmonary vascular leak.
Immunopharmacology and immunotoxicology 1994;16(2):139-48.
1993: J F Gera; C Fady; A Gardner; F J Jacoby; K B Briskin; Alan Lichtenstein
Inhibition of DNA repair with aphidicolin enhances sensitivity of targets to tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(7):3746-57.
1993: C Fady; A Gardner; J F Gera; Alan Lichtenstein
Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
Cancer immunology, immunotherapy : CII 1993;37(5):329-36.
1993: C Fady; A Gardner; J F Gera; Alan Lichtenstein
Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.
Cancer immunology, immunotherapy : CII 1993;36(5):307-14.
1993: Steven M Dubinett; Min Huang; S Dhanani; D Kelley; Alan Lichtenstein; W W Grody; L E Mintz
In situ regulation of pulmonary macrophage TNF-alpha mRNA expression by IL2.
Chest 1993;103(2 Suppl):91S-94S.
1992: Alan Lichtenstein; C Fady; J F Gera; A Gardner; V R Chazin; D Kelley; J Berenson
Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.
Cellular immunology 1992;141(1):219-32.
1992: C Fady; A M Gardner; J F Gera; Alan Lichtenstein
Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
Cancer research 1992;52(4):764-9.
1991: J F Gera; Alan Lichtenstein
Human neutrophil peptide defensins induce single strand DNA breaks in target cells.
Cellular immunology 1991;138(1):108-20.
1991: Marilene B Wang; Alan Lichtenstein; R A Mickel
Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1991;105(4):517-27.
1991: Alan Lichtenstein
Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane.
The Journal of clinical investigation 1991;88(1):93-100.
1991: Alan Lichtenstein; J F Gera; J Andrews; J Berenson; Carl Ware
Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(6):2052-8.
1990: Alan Lichtenstein; J Berenson; J F Gera; K Waldburger; O Martinez-Maza; J S Berek
Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.
Cancer research 1990;50(22):7364-70.
1990: Ronald L Paquette; J Berenson; Alan Lichtenstein; F McCormick; H Phillip Koeffler
Oncogenes in multiple myeloma: point mutation of N-ras.
Oncogene 1990;5(11):1659-63.
1990: B Strasnick; N Lagos; Alan Lichtenstein; R A Mickel
First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1990;103(4):537-49.
1989: F R Leess; J K Bredenkamp; Alan Lichtenstein; R A Mickel
Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
The Laryngoscope 1989;99(12):1255-61.
1989: Alan Lichtenstein; J Berenson; D Norman; M P Chang; A Carlile
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.
Blood 1989;74(4):1266-73.
1989: Alan Lichtenstein; M Seelig; Jonathan S Berek; J Zighelboim
Human neutrophil-mediated lysis of ovarian cancer cells.
Blood 1989;74(2):805-9.
1988: Alan Lichtenstein; C Spina; Jonathan S Berek; T Jung; J Zighelboim
Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Cancer research 1988;48(20):5853-9.
1988: R A Mickel; D J Kessler; J M Taylor; Alan Lichtenstein
Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.
Cancer research 1988;48(17):5017-22.
1988: Alan Lichtenstein
Neutrophil-mediated nonoxidative tumor lysis stimulated by high concentrations of phorbol myristate acetate.
Clinical immunology and immunopathology 1988;47(3):296-309.
1988: D J Kessler; R A Mickel; Alan Lichtenstein
Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma.
Archives of otolaryngology--head & neck surgery 1988;114(3):313-8.
1987: J Berenson; R Wong; K Kim; N Brown; Alan Lichtenstein
Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma.
Blood 1987;70(5):1550-3.
1984: Jonathan S Berek; R C Bast; Alan Lichtenstein; N F Hacker; C A Spina; L D Lagasse; R C Knapp; J Zighelboim
Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
Obstetrics and gynecology 1984;64(5):708-14.
1984: Alan Lichtenstein; Jonathan S Berek; R Bast; C Spina; N Hacker; R C Knapp; J Zighelboim
Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Journal of biological response modifiers 1984;3(4):371-8.
1983: Alan Lichtenstein; R Mickel; J Zighelboim
Inhibition of natural killer cell lysis by natural killer-inhibitory substance: mechanism of suppression.
Cellular immunology 1983;80(1):66-77.
1983: J Zighelboim; Alan Lichtenstein; A Bick; R Mickel
Inhibition of natural killer cell activity by a soluble substance released by rat peritoneal cells.
Cancer research 1983;43(5):1984-9.
1983: Alan Lichtenstein; A Bick; J Cantrell; J Zighelboim
Augmentation of NK activity by Corynebacterium parvum fractions in vivo and in vitro.
International journal of immunopharmacology 1983;5(2):137-44.
1982: Alan Lichtenstein; R Tuttle; J Cantrell; J Zighelboim
Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice.
Journal of the National Cancer Institute 1982;69(2):495-501.
1981: Alan Lichtenstein; R Murahata; M Terpenning; J Cantrell; J Zighelboim
Activation and mechanism of action of suppressor macrophages.
Cellular immunology 1981;64(1):150-61.
1981: Alan Lichtenstein; R Murahata; R Sugasawara; J Zighelboim
Suppressor T cells and suppressor macrophages induced by Corynebacterium parvum.
Cellular immunology 1981;58(2):257-68.